Claret Asset Management’s Biogen BIIB Stock Holding History

Claret Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Sell	1,063 -771	-42%	-$147K	0.02%	252
2026 Q1	$336K	Buy	1,834 +1	+0.1%	+$184	0.04%	163
2025 Q4	$323K	Sell	1,833 -5	-0.3%	-$817	0.04%	164
2025 Q3	$257K	Sell	1,838 -26	-1%	-$3.51K	0.03%	233
2025 Q2	$234K	Buy	+1,864	New	+$232K	0.03%	262

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Claret Asset Management's BIIB Position: Q2 2026 in Review

Claret Asset Management reduced its Biogen (BIIB) stake by 42% in Q2 2026, selling an estimated $147K and leaving 1,063 shares worth $230K. The position accounts for 0.02% of the portfolio, ranked #252.

Claret Asset Management first reported a position in BIIB in Q2 2025 and has held it in 5 quarters since. The position peaked at $336K in Q1 2026. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Claret Asset Management held 1,063 shares of Biogen worth $230K as of Q2 2026.
Claret Asset Management sold 771 Biogen shares in Q2 2026, an estimated $147K.
Biogen made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #252 holding.
Claret Asset Management first reported a position in Biogen in Q2 2025 and has held it in 5 quarters since.
Claret Asset Management's Biogen position peaked at $336K in Q1 2026.
1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.